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Cognitivedecline isassociatedwithgeneexpressionchanges in thebrain,but the transcriptionalmechanismsunderlyingmemory impairments
incognitivedisorders, suchasAlzheimer’sdisease (AD), are largelyunknown.Here,weaimedtoelucidate relevantmechanismsresponsible for
transcriptional changesunderlying earlymemory loss inADbyexaminingpathological, behavioral, and transcriptomic changes in control and
mutant-amyloidprecursorprotein(APPSw,Ind) transgenicmiceduringaging.Genome-widetranscriptomeanalysisusingmousemicroarrays
revealed deregulation of a gene network related with neurotransmission, synaptic plasticity, and learning/memory in the hippocampus of
APPSw,Indmiceafterspatialmemorytraining.Specifically,APPSw,IndmiceshowchangesonacAMP-responsiveelementbindingprotein(CREB)-
regulated transcriptional program dependent on the CREB-regulated transcription coactivator-1 (Crtc1). Interestingly, synaptic activity and
spatialmemory inducesCrtc1dephosphorylation (Ser151), nuclear translocation, andCrtc1-dependent transcription in thehippocampus, and
these events are impaired in APPSw,Ind mice at early pathological and cognitive decline stages. CRTC1-dependent genes and CRTC1 levels are
reduced in humanhippocampus at intermediate Braak III/IV pathological stages. Importantly, adeno-associated viral-mediated Crtc1 overex-
pression in the hippocampus efficiently reversesA-induced spatial learning andmemory deficits by restoring a specific subset of Crtc1 target
genes. Our results reveal a critical role of Crtc1-dependent transcription on spatial memory formation and provide the first evidence that
targeting brain transcriptome reversesmemory loss inAD.
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Introduction
Alzheimer’s disease (AD), the most common cause of dementia,
is characterized pathologically by abnormal accumulation of
-amyloid (A) peptides, hyperphosphorylated tau and synapse
dysfunction in the brain. The earliest cognitive symptoms of the
disease are temporally associated with progression of tau and
amyloid pathologies from the entorhinal cortex and hippocam-
pus to associative and temporal cortical areas (Braak et al., 2006).
Memory impairments in AD transgenic mouse models are evi-
dent before accumulation of amyloid plaques (Oddo et al., 2003;
Saura et al., 2005) suggesting that events downstream of A con-
tribute to synaptic changes early in the disease process. Among
these events, transcriptome changes affecting cell signaling, met-
abolic, inflammation and neurotransmission pathways precede
neuropathology in AD brains (Blalock et al., 2004; Bossers et al.,
2010; Twine et al., 2011). This raises the possibility that deregu-
lation of mechanisms controlling brain transcriptome may un-
derlie memory loss at early AD stages.
Activity-dependent gene transcription is essential for long-
lasting plastic changes in neuronal circuits encoding memory.
cAMP-responsive element binding protein (CREB)-dependent
transcription, which mediates neuronal excitability, synaptic
plasticity, and long-lasting memory in the hippocampus (Lee and
Silva, 2009), depends on the transcriptional coactivator CRTC1
(or mouse Crtc1) (Conkright et al., 2003b). In response to syn-
aptic activity, Crtc1 translocates from the cytosol to the nucleus
to increase CREB binding to specific gene promoters (Altarejos et
al., 2008; Espan˜a et al., 2010b; Ch’ng et al., 2012). Recent evidences
suggest that A negatively affect hippocampal synaptic plasticity,
memory and synapse loss by deregulating cAMP/Ca2-mediated
CREB signaling (Vitolo et al., 2002; Smith et al., 2009; Espan˜a et al.,
2010b). Consistently, CREB-signaling activation ameliorates learn-
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ing and/or memory deficits in transgenic AD mouse models (Gong
et al., 2004; Caccamo et al., 2010; Yiu et al., 2011). These results
suggest that disruption of CREB signaling may contribute to mem-
ory deficits in AD (Saura and Valero, 2011), but the specific CREB-
dependent gene programs that mediate early synaptic dysfunction
and memory loss in AD are unknown. A better understanding of
these mechanisms is crucial for elucidating new signaling pathways
for drug discovery in cognitive disorders.
To investigate the molecular mechanisms responsible for
transcriptome changes during the progression of AD, we per-
formed extensive pathological, behavioral, transcriptional, and
biochemical analyses in WT and APP transgenic mice at 2–18
months of age (Mucke et al., 2000). Genome-wide transcriptome
analyses were performed in naive and memory trained APPSw,Ind
transgenic mice at initial pathological and cognitive decline
stages. Microarray and bioinformatic enrichment analyses re-
vealed a set of CREB-dependent genes involved in synaptic func-
tion and plasticity deregulated in the hippocampus of APPSw,Ind
transgenic mice specifically after memory training. These tran-
scriptional changes were associated with Crtc1 dysfunction but
not CREB changes. Crtc1 overexpression in the hippocampus
efficiently reversed transcriptome and spatial learning and mem-
ory deficits in APPSw,Ind mice, suggesting that enhancing Crtc1
function may provide therapeutic benefits for transcriptome and
memory deficits at early AD stages.
Materials and Methods
Transgenic mice and human samples. APPSw,Ind transgenic mice (line J9)
expressing human APP695 harboring the FAD-linked Swedish (K670N/
M671L) and Indiana (V717F) mutations under the neuronal PDGF
promoter were obtained by crossing APPSw,Ind to nontransgenic (WT)
mice. Mice used in this study were age-matched male littermate control
and APPSw,Ind mice (C57BL/6 background). Human brain samples were
obtained from brain banks of Hospital de Bellvitge (Universitat de Bar-
celona, Spain) and Fundacio´n CIEN (Instituto de Salud Carlos III,
Spain). Brains samples were matched as closely as possible for sex, age
and postmortem interval. Neuropathology was classified according to
Braak staging for neurofibrillary tangles and neuritic plaques (Braak et
al., 2006). Experimental procedures were conducted according to the
Animal and Human Ethical Committee of the Universitat Auto`noma de
Barcelona (protocol CEEAH 1783, Generalitat Catalunya 6381) follow-
ing the European Union guidelines.
Viral constructs and transcriptional assays. Lentiviral Crtc1 shRNAs
were generated by transfecting pLVTHM containing mouse Crtc1 or
scramble ShRNA, pSPAX2 and pM2G vectors in HEK293T cells as de-
scribed previously (Espan˜a et al., 2010b). Adeno-associated virus (AAV)
AAV2/10-Crtc1-myc containing the AAV2 genome into AAV10 packing
vectors and under the chicken -actin promoter was generated by sub-
cloning pcDNA3-Crtc1-myc (Kova´cs et al., 2007) into pVAX1 (Invitro-
gene) and pGV-IRES2-GFP vectors. AAV were generated by transfecting
HEK293T cells with AAV2 recombinant, pRepAAV2/CapAAV10, and
pXX6 vectors. For transcriptional assays, hippocampal neurons were in-
fected at 3 DIV with scramble or Crtc1 shRNA lentivirus (2 transducing
units/cell) or AAV2/10-Crtc1 or AAV2/10-GFP virus (1  10 5 gc/cell).
Neurons (10 DIV) were transfected with pCRE-luc (0.5 g; Stratagene)
and TK renilla (0.25 g; Promega) plasmids using LipofectAMINE 2000
for 24 h before stimulation (FSK/KCl) for 4 h and analyzed with the
dual-luciferase activity assay (Promega) in a Synergy HT luminometer
(Bio-Tek; Espan˜a et al., 2010b).
ChIP analysis. Chromatin immunoprecipitation (ChIP) was per-
formed as described previously (Dahl and Collas, 2008; Espan˜a et al.,
2010b). Neurons (12–14 DIV) were treated with vehicle or FSK (20 M)
and KCl (30 mM) for 30 min. Cells were crosslinked with 1% formalde-
hyde, lysed in ChIP buffer (50 mM Tris-HCl, pH 8.1, 100 mM NaCl, 5 mM
EDTA, 1% SDS, 0,1% Na deoxycholate, and protease/phosphatase inhib-
itors) and sonicated. DNA (2.5 g) immunoprecipitations were per-
formed overnight in diluted ChIP buffer (0.1% SDS, 1.1% Triton X-100)
with rabbit CRTC1 and CREB antibodies or irrelevant IgGs (Cell Signal-
ing Technology). Immunoprecipitated DNA was decrosslinked and am-
plified by real-time PCR using specific primers for CRE-containing
promoter sequences of specific genes.
Behavioral studies and viral injections.The Morris water maze (MWM)
was performed in 3 d handled mice in a circular pool (90 cm diameter; 6.5
cm hidden platform) for three or five consecutive days (4 trials daily; 60 s
per trial; Espan˜a et al., 2010a). Mice were tested for memory retention
(probe trial) 2.5 h after training on day five, and they were killed 30 min
after training. We selected this time to get a measure of memory retention
while achieving a maximum peak of gene expression, which occurs
0.5–2 h after spatial training (Guzowski et al., 2001). The swimming
group moved freely in the maze without platform for 5 d and mice were
killed 30 min after a simulated probe trial. For viral injections, 6-month-
old mice (n  8 mice/group) were anesthetized with isofluorane and
placed in a stereotaxic platform (Kopf). The injection coordinates for the
hippocampus were as follows: anterior 0.2 caudal to bregma; 0.18 lateral
to bregma; depth 0.2 ventral to dural surface. AAV2/10-GFP or -Crtc1
viral stocks (3 l; 5.1 10 11 gc/ml; 0.5 l/min) were injected bilaterally
into the hippocampus. Three weeks after AAV injection mice were tested
in the water maze (120 cm circular pool; 11 cm platform) for 5 d (6 trials
daily; 60 s per trial), tested in a probe trial 2.5 h after training, killed, and
dissected. Importantly, both maze setups lead to similar values of escape
latencies during spatial training and memory retention in the probe trial
test in WT and APPSw,Ind mice (compare Figs. 1C, 4D). In all cases, spatial
learning and memory parameters were analyzed with SMART software
(PanLab; Espan˜a et al., 2010a).
Biochemical analysis. For biochemical analysis, naive and trained mice
were killed 30 min after training by cervical dislocation and whole hip-
pocampus dissected out and immediately frozen. Tissue was lysed in
cold-lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA,
0.5% Triton X-100, 1% NP-40, 0.1% SDS, 1 mM Na3VO4, 50 mM NaF, 1
mM PMSF) containing protease and phosphatase inhibitors (Roche). For
nuclear fractionation mouse forebrains were freshly dissected, gently ho-
mogenized in ice-cold sucrose buffer A (10 mM HEPES, pH 7.5, 200 mM
sucrose, 1.5 mM MgCl2, 10 mM KCl, protease/phosphatase inhibitors)
and centrifuged (1500 g, 15 min). The pellet was homogenized in 1.6 M
sucrose buffer, fractionated in 2.2–1.4 M sucrose gradients (100,000 g, 35
min, 4°C) and the pellet (nuclei) was lysed in buffer B (25 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1% NP-40, and 10% glycerol as described previously
(Thormodsson et al., 1995; Saura et al., 2004). Proteins were quantified with
the BCA protein assay kit (Pierce) and resolved by SDS-PAGE and Western
blotting. Protein bands were quantified with the ImageJ software within a
linear range of detection. The following antibodies were used: rabbit anti-
Crtc1, CREB, phosphorylated CREB (Ser133), and Nur77 (Cell Signaling
Technology); phosphorylated CRTC1 (Ser151; Espan˜a et al., 2010b); CBP
(A-22), BDNF, c-fos (4), rabbit c-myc (A-10), and c-myc (9E10) (Santa Cruz
Biotechnology); rabbit APP C-terminal antibody (Saeko; aa 665–695); rab-
bit APPs antibody (1736; aa 595–611) recognizing specifically cleaved
APPs C-terminus; Nurr1, GAPDH, -tubulin and -actin) (AC15) from
Abcam, and lamin B1 (Zymed).
Immunohistochemical and immunofluorescence staining. For A stain-
ing, sagittal brain paraffin sections (5m) were deparaffinized in xylene,
rehydrated, and incubated with 3% hydrogen peroxide as described pre-
viously (Espan˜a et al., 2010a). Sections were incubated in 60% formic
acid for 6 min to allow antigen retrieval, washed in 0.1 M Tris-HCl, and
incubated with anti-A (6E10; 1:1000; Signet) before immunoperoxi-
dase staining and analysis with a Nikon Eclipse 90i microscope. This
staining protocol was previously shown to label specifically A in APP
transgenic mice (Espan˜a et al., 2010a). For Crtc1-myc and Arc staining,
floating sections (40 m) were blocked in PBS containing 5% normal
goat serum and 0.2% Triton X-100 and incubated with rabbit anti-myc
(1:1000) and mouse anti-NeuN (1:2000; Millipore) antibodies or rabbit
anti-Crtc1 (1:300) and mouse anti-myc (1:500; 9E10) or anti-Arc (1:100;
Ab62142, Abcam) and the Alexa Fluor 488/594-conjugated goat second-
ary antibodies (1:400; Invitrogen) and Hoechst (1:10,000; Invitrogen).
For Crtc1 nuclear translocation analysis, mice were trained in the MWM
for 5 d and killed 30 min after training. Mice were deeply anesthetized
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with pentobarbital (200 mg/kg, i.p.) and int-
racardially perfused with saline and 4% buff-
ered formaldehyde. Paraffin sections (5 m)
were deparaffinized, microwave heated (10
min) in antigen retrieval citrate buffer and in-
cubated with CRTC1 (1:300; Cell Signaling
Technology) and MAP2 (1:300; Sigma-
Aldrich) antibodies and Hoechst followed by
AlexaFluor 488/594-conjugated goat IgGs. Im-
ages (20; zoom 0.5) of hippocampal subre-
gions (4 sections; n  5– 6/group) were
obtained with a Zeiss LSM700 laser scanning
microscope. Crtc1 nuclear staining intensity in
the selected regions was measured using a sum
projection of six Z-sections (1 m)/section).
Hoechst labeling was used to assign the region
of interest for nuclear Crtc1 staining, whereas 2
m area around the nucleus was considered
cytoplasmic. Crtc1 nuclear/cytoplasm inten-
sity ratio was calculated using ImageJ software
(v1.47n).
Microarray and bioinformatic analyses. For
microarray analyses, nontransgenic control
(WT) and APPSw,Ind mice (n  3– 4/group)
were handled and kept in the home cage (na-
ive) or trained in the MWM for five consecu-
tive days and tested in a probe trial 2.5 h later.
Trained mice were killed 30 min after the probe
trial by cervical dislocation. Hippocampi were
dissected on ice, immersed in RNAlater (R), and
stored at 80°C. RNA was purified using the
RNAeasy mini kit (Qiagen) and quality tested
by using the Agilent 2100 Bioanalyzer (Agilent
Technologies). Total RNA was amplified,
reverse-transcribed, and fluorescently labeled
with either Cy3-CTP or Cy5-CTP using the
Agilent Fluorescent Linear Amplification kit
(Agilent Technologies). Two individual sam-
ples labeled with Cy3 or Cy5 were hybridized
(64°C, 20 h) to the mouse Genome 32K Oligo
Array containing 33,696 transcripts (Capital-
Bio) by the Biotools Custom Microarray Ser-
vice (Biotools B&M Labs). After hybridization,
slides were washed, dried and scanned on a
LuxScan 10K Microarray Scanner (Capitalio)
and analyzed with LuxScan 3.0 Imaging and
Analysis software (LuxScan Technologies).
Microarray normalization was performed by
the Global loess method.
Microarray data were statistically analyzed
with the open source R statistical software
program v2.9.2 (http://www.r-project.org)
using the Linear Model for Microarray Data
(Limma) package in Bioconductor (http://
www.bioconductor.org/; Durinck et al., 2009).
Statistical gene expression differences between
the groups, calculated from measures of log2-
fold-change (M values), were analyzed with a
linear model and empirical Bayes using the
Limma package (Smyth, 2005). The p values
correction for multiple testing was performed
using Benjamini and Hochberg algorithm
(Benjamini and Hochberg, 1995). Statistical
gene changes1 or1 and corrected p val-
ues 0.05 were considered significant. Mouse microarray data are avail-
able at the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under
accession number E-MTAB-2067. Gene ontology (GO) analysis of
mouse microarray data were performed with ClueGO v1.4 (Bindea et al.,
2009) using the following parameters: enrichment/depletion two-sided
hypergeometric statistical test; correction method: Bonferroni; GO term
range levels: 3– 8; minimal number of genes for term selection: 5; mini-
mal percentage of genes for term selection: 10%; -score threshold: 0.5;
general term selection method: smallest p value; group method: ; min-
imal number of subgroups included in a group: 3; minimal percentage of
shared genes between subgroups: 50%.
Figure 1. Age-dependent pathological, memory and gene expression changes in APPSw,Ind mice. A, Age-dependent amyloid
pathology in the hippocampus of APPSw,Ind (APP) mice. Brain sections were stained with an anti-A 6E10 antibody. M, months;
Hip, hippocampus; Cx, cortex. Scale bars: Hp, 250m; Cx, 20m. B, Biochemical analysis of APP and APP C-terminal fragment
(CTF; “Saeko” antibody) and -secretase-derived APPs fragment (1736 antibody) in hippocampus of WT, APPSw,Ind and
presenilin-1 (PS1) conditional knock-outmouse (PS1cKO).C, Age-dependent spatialmemorydeficits inAPPSw,Indmice analyzed as
number of target platform crossings and percentage time in the target quadrant in the probe test in the MWM. Data are mean	
SEM (n 7–8mice/group); *p 0.05, **p 0.001.D, E, Micewere trained for 5 d in thewatermaze () or treated identically
without training () before analysis of c-fos and Bdnf IV mRNAs by qRT-PCR in different brain regions. Levels of mRNA were
normalized toGapdh. Values representmean	 SEM (n 4–5mice/group); *p 0.01, **p 0.001, ***p 0.0001 compared
with controls. #p 0.01, ##p 0.001 comparedwith nontrained. F, Expression of activity-dependent genes in trained APPSw,Ind
hippocampus at 2–18months. Values represent gene changes relative to trained nontransgenic controls. Data representmean	
SEM (n 4–6mice/group); *p 0.05, **p 0.001, ***p 0.0001 compared with trained controls. Statistical analyses were
determined by two-way ANOVA followed by Scheffe´’s S post hoc test.
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The CREB-regulated transcriptome consisted of 287 genes, which con-
tained CRE sequences and at least a TATA box in their promoter randomly
selected from the CREB Target gene database (http://natural.salk.
edu/CREB), and 63 confirmed CREB target genes (Zhang et al., 2005). The
CREB gene list was filtered in the whole microarray data according to the
above statistical criteria. Heat maps were computed with Mayday software
2.10 (Battke et al., 2010). Differentially expressed CREB genes were submit-
ted to an ontology term enrichment analysis using DAVID (Huang da et al.
2009). Filters used in the functional annotation clusters were established as
follows: Similarity Term Overlap 3, Similarity Threshold 0.50, Initial Group
size 5, final Group Membership 5, and Multiple Linkage Threshold 0.70.
Quantitative real-time RT-PCR. Human hippocampal RNA was iso-
lated using a combination of Trizol method (Life Technologies) and the
RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions.
Purified mouse RNA (1 g; RIN 8.0) and human RNA (2 g; RIN
6.0) were reverse-transcribed and amplified using Power SYBR Green
PCR Master Mix (15 l; Invitrogen) in an Applied Biosystems 7500 Fast
system. Data analysis was performed by the comparative 
Ct method
using the Ct values and the average value of PCR efficiencies obtained
from LinRegPCR software. Gene expression in mouse samples was nor-
malized to Gapdh or the geometric mean of three of the most stable
following genes determined in each experiment: Gapdh, hypoxanthine
guanine phosphoribosyl transferase (Hprt), peptidylprolyl isomerase A
(Ppia), and -actin or TATA box binding protein (Tbp; Vandesompele et
al., 2002). Human genes were normalized to the geometric mean of
GAPDH, ACTB, and PPIA, which were the three more stable genes found
from the Human Reference Gene Panel (TATAA Biocenter AB).
Statistical analysis. Statistical analysis was performed using one-way
ANOVA and Bonferroni or Student-Newman–Keuls post hoc tests. The
behavioral data were analyzed using two-way ANOVA with repeated
measures and Scheffe´’s S for post hoc comparisons by using the SuperA-
NOVA program v1.11. Data represent the mean 	 SEM. Differences
with p 0.05 were considered significant.
Results
Altered activity-dependent genes are associated with early
memory loss in an ADmouse model
To elucidate transcriptional mechanisms underlying early mem-
ory loss in AD, we first analyzed pathological and cognitive
changes in a -amyloid precursor protein (APPSw,Ind) transgenic
mouse that develops AD-like pathological changes (Mucke et al.,
2000; Espan˜a et al., 2010a). APPSw,Ind transgenic mice show ab-
sence of cerebral A staining at 2 months, intracellular A accu-
mulation in the hippocampus at 6 months and amyloid plaques
in hippocampus and cortex at 12–18 months (Fig. 1A). Levels of
human APP were similarly increased (2-fold) in APPSw,Ind at 2
months (1 	 0.15-fold), 6 months (0.96 	 0.1-fold), and 12
months (1 	 0.1-fold; Fig. 1B). To examine -, -, and
-secretase-mediated APP processing we performed biochemical
analyses of /-secretase-derived soluble(s) APPs and APP
C-terminal fragments (CTFs). Levels of APPs were similar,
whereas APP CTFs were absent, in the hippocampus of APPSw,Ind
mice at 2–12 months of age (Fig. 1B), indicating increased A but
unchanged -, -, and -secretase-mediated APP processing in
APPSw,Ind mice during aging. We next used the MWM test to
evaluate hippocampal-dependent spatial memory, a type of
memory altered in AD patients at early disease stages (deIpolyi et
al., 2007; Laczo´ et al., 2011). Two-month-old APPSw,Ind and con-
trol mice showed similar escape latencies during training, as re-
vealed by a statistically significant day effect (two-way ANOVA:
F(4,60) 15.01; p 0.0001) but no genotype effect (F(1,60) 0.31,
p 0.05), and a significant preference for the target quadrant in
the probe trial (quadrant effect, F(3,48) 9.1, p 0.0001) without
significant effect of genotype (F(1,48)  3.45, p  0.05; Fig. 1C;
data not shown). By contrast, APPSw,Ind mice starting at 6 months
spent significantly longer latencies during training (two-way
ANOVA, genotype effect, 6 months: F(1,70) 21.2, p 0.0001; 12
months: F(1,50) 59.6, p 0.0001, and 18 months: F(1,70) 41.5,
p 0.0001; Fig. 1C; data not shown). APPSw,Ind mice developed
age-dependent long-term spatial memory deficits starting at 6
months as confirmed by significant reduced target quadrant per-
manencies (genotype effect, F(1,50)  13.3; p 0.001; age effect:
F(3,50) 0.46; p 0.71) and number of target crossings (genotype
effect, F(1,50) 13.5; p 0.001; age effect: F(3,50) 3.14; p 0.03)
in the probe test (Fig. 1C). Groups did not differ in latencies to
find the visible platform or swimming speeds ruling out the pos-
sibility of visual/motor disturbances in transgenic mice.
To evaluate whether our spatial training protocol was efficient
to induce expression of memory-dependent genes, we analyzed
by quantitative real-time RT-PCR (qRT-PCR) the levels of
activity-dependent CREB target genes, such as c-fos and Bdnf, in
basal and trained conditions as previously reported (Guzowski et
al., 2001). Spatial training for 3 or 5 d, but not swimming without
spatial cues, induced expression of c-fos and Bdnf (exon IV) tran-
scripts in the hippocampus and/or neocortex but not the cerebel-
lum (Fig. 1D,E; data not shown). Interestingly, c-fos and Bdnf
levels were significantly reduced in APPSw,Ind mice after spatial
training but not in basal conditions starting at 6 months (Fig.
1D–F). By contrast, levels of CREB target genes Egr-1 and Cyr61
were unchanged in naive and trained APPSw,Ind mice at 2–18
months (Fig. 1F). These results suggested altered expression of
CREB target genes regulated by spatial training coinciding with
early pathological and memory changes in APPSw,Ind mice.
Altered CREB-dependent transcriptome in APPSw,ind mice
To identify gene expression changes associated with early memory
deficits in AD, we performed genome-wide transcriptome profile
analyses by using mouse cDNA microarrays in the hippocampus of
6-month-old nontransgenic (WT) and APPSw,Ind mice in two dis-
tinct experimental situations: nontrained (naive) and spatial trained
conditions (Fig. 2A). Using a linear regression model and empirical
Bayes analysis (using1 log2-fold 1 and p 0.05 as statistical
criteria), we identified 28 genes (17 upregulated and 11 downregu-
lated) of 33,696 transcripts represented on the mouse genome mi-
croarray differentially expressed in APPSw,Ind mice in basal
conditions. By contrast, 932 genes (88% downregulated and 12%
upregulated) were differentially expressed in APPSw,Ind mice com-
pared with WT mice after spatial training (Fig. 2A). The microarray
data are available in the functional genomic database ArrayExpress
(www.ebi.ac.uk/arrayexpress; E-MTAB-2067). Gene-annotation
enrichment analysis based on ClueGO, a computational tool that
integrates GO terms as well as Kyoto encyclopedia of genes and
genomes (KEGG)/ BioCarta pathways (Bindea et al., 2009), re-
vealed a number of functional biological pathways associated
with these differentially transcribed genes in trained APPSw,Ind mice.
The biological network with the most significant k score ( 0.5)
contains 164 differentially expressed genes grouped in several func-
tional GO terms. This network is depicted in Figure 2B as functional
biological terms represented as nodes of different colors and sizes,
which reflect the enrichment significance of the term, as well as the
interrelations (indicated by connecting lines according to k score) of
functionally related biological groups deregulated in spatial trained
APPSw,Ind mice. Interestingly, 70 genes of this network are included
in five principal biological groups: learning, regulation of neurolog-
ical system, long-term depression, long-term potentiation, and oxi-
dative phosphorylation (Fig. 2B; Table 1). Specifically, the “learning”
group is a significant term within the network because it contains five
interconnected subgroups (n number of genes): learning (n 10),
memory (n5), learning or memory (n12), visual learning (n5),
Parra-Damas, Valero et al. • CRTC1 Signaling in Alzheimer’s Disease J. Neurosci., April 23, 2014 • 34(17):5776–5787 • 5779
and associative learning (n 7). Notably, AD (KEGG:05010) was the
functionaltermwiththelargestnumberofdifferentiallyexpressedgenes
of the total of the term (10.53%;n20 genes of 190 genes of the term).
However, the AD term was not linked to other groups as it was not
sharing enough percentage of genes with any other term.
To identify potential CREB target genes differentially ex-
pressed after memory training, we filtered in the raw microarray
data 350 genes obtained from the CREB target gene database
(http://natural.salk.edu/CREB). Selected genes contained CRE
promoter sequences localized within 250 base pairs from the
TATA box, a distance that is required for robust transcriptional
induction (Conkright et al., 2003a; Zhang et al., 2005). Whereas
gene expression profile was similar between naive control and
APPSw,Ind mice, 49 CREB target genes (45 downregulated and 4
upregulated) were differentially expressed in spatial trained
APPSw,Ind mice (Fig. 2C; Table 2). Functional enrichment analysis
using DAVID identified several biological groups associated with
these genes including metabolism (15%), cell signaling (14%),
cell adhesion (13%), neuronal transmission/plasticity/neurito-
genesis (30%), transcriptional regulation (10%), vesicular traf-
ficking (7%), translation (4%), cell survival (4%), and protein
degradation (3%). Expression of genes related to synaptic trans-
Figure2. Hippocampal transcriptome changes in spatial trained APPSw,Indmice.A, Experimental design of the groups used for gene profiling analyses (top) and Venn diagram (bottom) showing
the number of genes differentially expressed in the hippocampus of APPSw,Ind mice versus control mice in themicroarray analysis. B, ClueGO analysis of the whole genemicroarray results showing
the most significant functional gene network (k score 0.5) altered in the hippocampus of spatial memory trained APPSw,Ind mice compared with trained WT mice. Biological pathways are
visualized as colored nodes linkedwith related groups based on their score level (0.3). The node size reflects the enrichment significance of the term and functionally related groups are linked.
Not grouped terms are shown inwhite. C, Heatmapof the normalized gene data showing differential expression of CREB target genes in the hippocampus of naive (four top lines) and spatial trained
(three bottom lines) APPSw,Indmice versusWTmice. Blue and red indicate genes downregulated or upregulated in APPSw,Indmice comparedwithWTmice. (D, E) Expression of genes associatedwith
neurotransmission and synaptic plasticity quantified by qRT-PCR in the hippocampus of spatial trained WT and APPSw,Ind mice at 6 months (D) and 2 months (E). Values represent fold gene
changes	 SEM (n 4–5mice/group). Valueswere normalized to the geometricmean of Ppia, Hprt, and-actin. Bdnf refers to Bdnf IV; *p 0.05, **p 0.001 (D, E), comparedwithWT control
or naive. Statistical analyses were determined by one-way ANOVA followed by Bonferroni post hoc test.
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mission and plasticity was validated by qRT-PCR. Thus, Arc,
c-fos, neurofilament (Nefl), nuclear receptor sub 4, 1, and 2 (Nr4a1,
Nr4a2), secretogranin II (Scg2), synaptotagmin IV (syt4), chromo-
granin A (Chga), transducer of ErB-2 (Tob1; p  0.18), Rab2a
(10% decrease), and Ptp4a1 (14% decrease) were downregulated
in the hippocampus of trained APPSw,Ind mice at 6 months (p
0.05) but not at 2 months (Fig. 2D,E). These results suggested
deregulation of a specific CREB-dependent gene program asso-
ciated with early memory loss in trained APPSw,Ind mice.
Activity-dependent Crtc1 transcription is deregulated in
APPSw,ind mice
We next investigated the molecular mechanisms underlying dif-
ferential deregulation of CREB target genes in APPSw,Ind mice.
Biochemical analysis revealed similar levels of phosphorylated
(pSer133) and total CREB (WT: 1.0 	 0.1 vs APPSw,Ind: 1.2 	
0.1-fold change) in the hippocampus of 6-month-old naive
control and APPSw,Ind mice (p  0.05; Fig. 3A). Spatial training
similarly enhanced CREB phosphorylation in control (1.8	 0.2-
fold) and APPSw,Ind (2.2	 0.4-fold) mice (one-way ANOVA, p
0.05). Total levels of Crtc1 were similar in naive or trained WT
and APPSw,Ind mice (naive mice, WT: 1.0 	 0.1 vs APPSw,Ind:
1.0 	 0.07-fold change). By contrast, phosphorylated Crtc1 at
Ser151, a site that regulates Crtc1 nuclear translocation and
transcription (Altarejos et al., 2008; Espan˜a et al., 2010b), was
significantly increased in naive APPSw,Ind mice (p 0.02). Inter-
estingly, spatial training significantly decreased Crtc1 phosphor-
ylation in both genotypes, although levels of phosphorylated
Crtc1 were significantly higher in APPSw,Ind mice (p 0.04; Fig.
3A). Reduced levels of Crtc1, but not CREB, phosphorylated
CREB or CBP, were found in nuclear fractions of APPSw,Ind fore-
brains (Fig. 3B). Confocal microscopy analysis revealed a clear
increased of Crtc1 in the nucleus of CA3 pyramidal neurons of
WT mice after spatial training (nucleus/cytoplasm ratio, trained:
1.25 vs naive: 1.0), whereas nuclear Crtc1 was reduced in trained
APPSw,Ind mice (1.05; Fig. 3C). By contrast, Crtc1 nuclear trans-
location was more diffuse and sparser in dentate gyrus (DG)
granular neurons and occurs only in specific CA1 pyramidal neu-
rons in WT but not APPSw,Ind mice after spatial training (Fig. 3C).
These results raised the possibility that Crtc1 dysfunction
could cause transcriptional changes in APPSw,Ind mice. To ana-
lyze this possibility, we examined whether the above CREB target
genes were dependent on Crtc1. In 10 DIV primary neurons,
synaptic activity significantly enhanced (5- to 100-fold) the
expression of Arc, c-fos, Nefl, Nr4a1, Nr4a2, Scg2, Syt, and Bdnf,
whereas only slightly increasedChga, Tob1, andCyr61 levels (1.5-
fold; Fig. 3D). A Crtc1 shRNA (Espan˜a et al., 2010b), which effi-
ciently decreasesCrtc1 transcripts (scramble: 100	 10% vs Crtc1
shRNA: 23.3 	 1.7%, p  0.0001 by one-way ANOVA) and
CREB transcriptional activity (scramble shRNA: 12.5 	 0.9 vs
Crtc1 shRNA: 5.8	 0.8-fold, p 0.0001 by one-way ANOVA),
significantly reduced expression of those genes, whereas barely
affectedTob1 andCyr61 (Fig. 3D). Interestingly,Crtc1 transcripts
were decreased by synaptic activity, suggesting that sustained
neuronal activity downregulates Crtc1 expression. Western blot-
ting analysis confirmed increased Nr4a1 (NUR77), Nr4a2
(NURR1), c-Fos, and BDNF proteins in response to neuronal
activity and their Crtc1 dependency (Fig. 3E). ChiP analyses us-
ing antibodies against Crtc1 and CREB (positive control) and an
irrelevant IgG (negative control) demonstrated that Crtc1 is spe-
cifically recruited to the promoter regions of c-fos, Nr4a1, and
Nefl but not Cyr61 in an activity-dependent manner, which con-
trasts with binding of CREB to c-fos,Nr4a1, andCyr61 promoters
independently of stimulus (Fig. 3F). Finally, CA3 pyramidal neu-
rons expressing high Crtc1 levels show elevated Arc expression
compared with neurons with low or very low Crtc1 (Fig. 3G).
Crtc1 overexpression rescues amyloid-induced
transcriptional and cognitive deficits
The above results suggested that disruption of Crtc1 could medi-
ate early A-induced transcriptional and memory deficits. As a
proof of concept, we expressed Crtc1-myc in vivo by using AAV
Table 1. Genes and functional groups of the relevant gene network deregulated in the hippocampus of trained APPSw,Ind mice
Group GO term Associated Genes (%) Corrected p value Group/term genes
1 Learning 15.38 0.0004 Apbb1, Atp1a2, Chst10, Gabra5, Gria1, Hif1a,Mecp2, Neto1, Neurod2, Ntan1, Ptn, Vdac1
2 Regulation of neurological system 25.00 0.0002 Camk2a, Hras1,Mecp2,Mgll, Neto1, Neurod2, Ppp3ca, Prkce, Prkcz, Rnf10, Serpine2,
Slc1a3, Snca, Ywhag
3 Long-term depression 15.28 0.00001 Adcy9, Calm1, Calm2, Camk2a, Camk2g, Gna11, Gnao1, Gria1, Gucy1b3, Hras1, Itpr1,
Jun,Map3k4,Mapk1, Ppp2ca, Ppp2cb, Prkcb, Prkcc, Tubb3
4 Oxidative phosphorylation 10.74 0.00001 1110020P15Rik, Atp1a1, Atp1a2, Atp5o, Atp6v0a1, Atp6v0d1, Atp6v0e2, Atp6v1c1,
Atp6v1d, Atp6v1g2, Cox15, Cox4i1, Cox7a2l, Cox7c, Cplx1, Ndufb2, Ndufb8, Ndufc2,
Sdhb, Syt1, Vamp2
5 Long-term potentiation 18.84 0.001 Abl1, Adcy9, Atp1a1, Atp1a2, Calm1, Calm2, Camk2a, Camk2g, Crk, Gna11, Gnao1,
Gng10, Gria1, Gucy1b3, Hras1, Itpr1, Jun,Map3k4,Mapk1, Ppp1ca, Ppp2ca, Ppp2cb,
Ppp2r2c, Ppp2r5a, Ppp3ca, Ppp3cb, Prkcb, Prkcc, Rpl3, Skp1a, Slc12a2, Tubb3,
Vamp2, Ywhag
Significant nongrouped terms
None Alzheimer’s disease 10.53 0.0002 1110020P15Rik, Apbb1, Apoe, Atp5o, Calm1, Calm2, Capn2, Cox4i1, Cox7a2l, Cox7c,
Itpr1, Lpl,Mapk1, Ndufb2, Ndufb8, Ndufc2, Ppp3ca, Ppp3cb, Sdhb, Snca
None Spliceosome 11.43 0.0007 Cwc15, Dhx15, Hnrnpk, Hspa8, Lsm4, Lsm5, Ncbp2, Nhp2l1, Prpf19, Sf3a3, Sf3b5, Sfrs7,
Snrpb, Snrpb2, Snrpd3, Syf2
None Glutamatergic synapse 10.85 0.004 Adcy9, Dlgap1, Glul, Gnao1, Gng10, Gria1, Itpr1,Mapk1, Ppp3ca, Ppp3cb, Prkcb, Prkcc,
Slc1a3, Slc38a1
None Regulation of insulin secretion 26.32 0.0143 Hif1a, Nnat, Pfkm, Ppp3cb, Prkce
None GTP binding 14.81 0.017 Arf1, Arf3, Arf5, Arl3, Gnao1, Hras1, Rraga, Rragb
None Metencephalon development 13.12 0.039 Hspa5, Kat2a, Ldb1,Mecp2, Neurod2, Pfdn1, Sdf4, Serpine2
None GABAergic synapse 10.90 0.041 Adcy9, Gabarap, Gabarapl1, Gabra5, Glul, Gnao1, Gng10, Prkcb, Prkcc, Slc38a1
Genes are grouped according to their biological function as determined by GO analysis of the mouse microarray data using ClueGO v1.4. Associated genes indicates the percentage of changed genes of the total of genes of the term.
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vector AAV2/10, a serotype characterized by high and specific
gene transduction in neurons of the brain (Klein et al., 2008).
AAV-Crct1 efficiently expressed functional Crtc1-myc as shown by
enhancement of synaptic activity-induced Crtc1-myc nuclear trans-
location (data not shown) and CREB-dependent transcription by a
CRE-luciferase assay in hippocampal neurons (AAV-GFP: vehi-
cle, 0.10 	 0.01 and FSK/KCl, 9.3 	 2.0; AAV-Crtc1: vehicle,
0.17 	 0.04 and FSK/KCl, 16.8 	 4.2-fold change; one-way
Table 2. Potential CREB target genes differentially expressed in the hippocampus of trained APPSw,Ind
Biological pathway/gene Gene GenBank Log fold-change p Biological function
Metabolism
Lactate dehydrogenase A Ldha NM_010699 5.08 0.0001 Conversion of L-lactate to pyruvate
ATP synthase subunit c1 Atp5g1 NM_007506 4.00 0.001 ATP synthesis
Glu oxaloacet transaminase1 Got1 NM_010324 3.71 0.001 Aspartate aminotransferase activity
Enolase 2/-enolase Eno2 NM_013509 3.03 0.028 Glycolysis
Na/K ATPase1 Atp1a1 NM_144900 2.37 0.01 Na/K transport, ATP synthesis
Isopentenyl-diphosphate -isomer1 Idi1 NM_145360 1.86 0.008 Isoprenoid biosynthetic pathway
Solute carrier family 38 Slc38a1 NM_134086 1.38 0.011 Glutamine transporter
Uncoupling protein 2 Ucp2 NM_011671 1.12 0.041 Mitochondria proton uncoupling
Pyruvate dehydrogenase kinase 4 Pdk4 NM_013743 1.78 0.019 Pyruvate metabolism
N()-acetyltransferase 50 Naa50 NM_028108 1.12 0.025 Acetyltransferase activity
Neurotransmission, plasticity, ves traff
Neuritin/cpg 15 Nrn1 NM_153529 4.34 0.001 Neuritogenesis, synaptic plasticity
Secretogranin II Scg2 NM_009129 3.76 0.007 Vesicle release, neuromodulation
Glutamate receptor GluA1 Gria1 NM_008165 3.00 0.005 Neurotransmission, memory
Syntaxin 4A Stx4a NM_009294 2.28 0.004 Docking of synaptic vesicles
Synaptotagmin IV Syt4 NM_009308 1.99 0.004 Exocitosis of synaptic vesicles
Chromogranin A Chga NM_007693 1.50 0.033 Vesicle release, neuromodulation
RAB2A Rab2a NM_021518 1.42 0.002 Protein transport from ER to Golgi
Syntaxin 18 Stx18 NM_026959 1.40 0.042 SNAP receptor
Leucin rich repeat TM Neuronal 1 Lrtm1 NM_028880 1.36 0.049 Synapse formation, axon traficking
Cell adhesion/cytoskeleton
Claudin 5 Cldn5 NM_013805 2.92 0.02 Component of tigh junctions
Neurofilament, light peptide Nefl NM_010910 2.60 0.0001 Neurofilament member
Fibronectin 1 Fn1 NM_010233 2.38 0.042 Cell adhesion and migration
Brain angiogenesis inh 1-ass.prot 2 Baiap2 NM_130862 2.25 0.01 Actin cytoskeleton, neuritogenesis
Angio-associated migratory protein Aamp NM_146110 1.69 0.003 Cell migration
Chondroitin sulfate proteoglycan 5 Cspg5 NM_013884 1.64 0.013 Dendritic branching and synapses
Calsyntenin 3 Clstn3 NM_153508 1.46 0.005 Cell adhesion, associative learning
Myelin oligodendrocyte glycoprotein Mog NM_010814 1.18 0.002 Maintenance myelin sheath
Neurocan Ncan NM_007789 1.14 0.03 Neuronal adhesion, neurite growth
Cell signaling
Protein phosph 1, reg sub 11 Ppp1r11 NM_029632 2.29 0.02 Inhibitor of PP1
TrkB Ntrk2 NM_008745 2.16 0.02 BDNF, NT-3/4/5 receptor
P tyrosine phosphatase 4a1 Ptp4a1 NM_011200 2.15 0.03 Protein tyrosine phosphatase
Transducer of ErbB-2.1 Tob1 NM_009427 1.93 0.02 Antiproliferation, learning/memory
Regulator of G-protein signaling 4 Rgs4 NM_009062 1.83 0.02 Regulates GTPase activity
Cyclin-dependent kinase 5 Cdk5 NM_007668 1.32 0.002 Neurodegen., associative memory
Disabled homolog1 Dab1 NM_010014 1.13 0.03 Adapter molecule, neural develop.
Cyclin-dependent kinase 16 Cdk16 NM_011049 1.09 0.03 Neurite outgrowth, neuron migration
Transcriptional regulation
Histone cluster 1, H2bj Hist1h2bj NM_178198 3.58 0.001 Compaction of chromatin
Activating Transcriptional factor 4 Atf4 NM_009716 3.29 0.004 Transcription activator, binds to CRE
Jun oncogene Jun NM_010591 2.64 0.002 Transcription factor
Inhibitor of DNA binding 2 Id2 NM_010496 2.3 0.032 Inhibitor of transcription factors
Nuclear receptor sub 4, 2 Nr4a2 NM_0113613 1.80 0.007 Transcription factor
Nuclear receptor sub 4, 1 Nr4a1 NM_010444 1.74 0.028 Transcription factor
Polymerase (RNA) II polypeptide K Polr2k NM_023127 1.013 0.042 RNA polymerase
Translation/cell survival
Poly(A)binding protein, cytoplas. 1 Pabpc1 NM_008774 3.75 0.003 Poly(A) translation, initiation
Translation initiation factor 3, sub D Eif3d NM_018749 1.92 0.009 Component of the eIF-3 complex
Programmed cell death 7 Pdcd7 NM_016688 1.43 0.025 Promotes apoptosis
Protein Degradation
Myeloid leukemia factor 2 Mlf2 NM_145385 3.03 0.0001 Protein degradation tagging activity
Ubiquitin-conjugated enzyme E2G 1 Ube2g1 NM_025985 1.31 0.041 Attachment of ubiquitin to proteins
Unclassified
Abhydrolase domain containing 11 Abhd11 NM_145215 2.38 0.001 Deleted Williams-Bernes syndrome
Relative mRNA levels in the hippocampus of APPSw,Ind mice compared to nontransgenic control mice after spatial training in the MWM. Relevant genes from microarray hybridizations are listed in each column, with log2-fold changes
indicating relative decrease (1) or increase (1) ofmRNA levels in APPSw,Indmice comparedwith controls. Genes are grouped according to their biological pathway and relative gene expression changes. A gene could be assigned tomore
than one biological function term. Only genes with p 0.05 are given.
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ANOVA, p  0.03). Viral injections were localized in the septal
(dorsal) hippocampus since this region is critical for spatial
water-maze acquisition and memory (Moser et al., 1995). AVV-
Crtc1 injection resulted in stable and long-term (1 month)
expression ofCrtc1-myc mRNA and protein mainly in neurons of
CA1 and CA3 pyramidal layers, stratum oriens, and hilus of the
DG (Figs. 4A–C, and data not shown). Crtc1-myc overexpression
lead to an increase of Crtc1-myc nuclear translocation in AVV-
Crtc1-myc injected mice (data not shown). The performance of
all groups improved significantly during spatial training in the
water maze (day 1 vs day 5, p 0.001), although the latencies of
AAV-GFP-injected APPSw,Ind mice were significantly higher than
the rest of groups (two-way ANOVA, genotype effect: F(3,135) 
10.2; day effect: F(4,135) 45.6; p 0.0001; Fig. 4D). In the probe
test, nontransgenic mice injected with AAV-GFP and AAV-
Crtc1, and APPSw,Ind mice injected with AAV-Crtc1 displayed
Figure 3. Reduced Crtc1 dephosphorylation, nuclear translocation and activation in APPSw,Indmice.A, Biochemical analyses of Crtc1, pCrtc1 (Ser151), CREB, and pCREB (Ser133) in hippocampus
of naive andmemory trained control (WT) and APPSw,Ind mice. Values represent fold changes	 s.e.m (n 4mice/group); *p 0.05, **p 0.002, and #p 0.05 compared with naive andWT
mice, respectively.B, Reduced Crtc1 and unchanged CBP, CREB, and pCREB in purified nuclear brain extracts of trained APPSw,Indmice. Data are themean	 SEM (n 3–4mice/group); *p 0.05
comparedwith controls. C, Confocal images showing localization of Crtc1 (green) andMAP2 (red) in DG, CA1, and CA3 hippocampus in naive and spatial trainedmice. Nuclear translocation of Crtc1,
as revealed by colocalizationwith Hoechst (blue; arrowheads) ismore evident in CA3 hippocampal neurons ofWTmice after spatial training, and reduced in trained APPSw,Indmice. CA3: Green Crtc1
staining in the left side of the images represents terminal axons fromDG granular cells (mossy fibers), whereas dendritic MAP2 staining (red) is detected as punctuate staining due to its transversal
position in the coronal sections. Images (20, zoom 0.5) are representative of n 5–6 mice/group. Scale bar, 40m. D, Expression of CREB target genes in 10 DIV cultured neurons expressing
scramble or Crtc1 shRNAs treated with vehicle () or FSK/KCl (). Data are normalized to Gapdh and represent the mean	 SEM (n 3); #p 0.0001, *p 0.05, **p 0.01 compared with
vehicle-treated or FSK/KCl-treated control neurons. E, Protein levels of Crtc1-dependent genes in noninfected (NI) or scramble (Scr)- or Crtc1 shRNA-infected neurons (10 DIV; n 4–5 cultures per
group); *p0.05, **p0.01 comparedwith scramble-FSK/KCl. Values arenormalized to-tubulin.F, ChiP analysis showsactivity-dependent recruitmentof Crtc1 to specific genepromoters. IgG,
Irrelevant antibody. Data represent themean	 SEM of three independent experiments; *p 0.05, **p 0.005, comparedwith IgG FSK/KCl IP.G, Expression of Arc (green) is evident in neurons
expressing high Crtc1 levels (red; arrowheads) compared with neurons with very low Crtc1 levels (arrows) in CA3 hippocampus of WT trained mice. Scale bar, 20 m. Statistical analysis was
determined by one- or two-way ANOVA followed by Student-Newman–Keuls post hoc test.
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significantly higher occupancies and number of crossings in the
target quadrant/platform relative to other quadrants (p 0.001),
whereas APPSw,Ind mice injected with AAV-GFP failed to show
such a preference (p 0.9; two-way ANOVA, Scheffe´’s S post hoc
test; Fig. 4D). Notably, Crtc1 gene delivery significantly increased
Arc, Nr4a1, Nr4a2, and Syt4 levels in control and APPSw,Ind mice,
which were significantly different from those of AAV-GFP-injected
APPSw,Ind mice, but decreased Chga, Scg2 and Cyr61 or unaffected
c-fos,Tob1, andTbp (Fig. 4E). These results demonstrated that Crtc1
efficiently ameliorates hippocampal-dependent learning and mem-
ory deficits in APPSw,Ind mice by enhancing the expression of a spe-
cific subset of Crtc1 target genes.
CRTC1-dependent transcriptional changes at early AD stages
To investigate changes in CRTC1-dependent genes during the
progression of AD pathology, we analyzed gene expression in the
hippocampus of 68 individuals pathologically classified as con-
trols (no pathology, n 16), early (Braak I–II, n 22), interme-
diate (Braak III–IV, n 14), and advanced (Braak V–VI, n 16)
AD pathological cases (Braak et al., 2006). Brain samples were
closely matched for age, neurofibrillary pathology, postmortem
delay and RIN values (Table 3). To faithfully compare gene ex-
pression across different pathological stages, transcripts were
normalized to the geometric mean of multiple reference genes
(Vandesompele et al., 2002). We observed a differential pattern of
Figure 4. Adeno-associated viral-mediated Crtc1 overexpression prevents early A-induced transcriptional and memory deficits. A, Long-term Crtc1-myc expression in the mouse dorsal
hippocampus. Overexpression of Crtc1-myc (green) in CA3pyramidal neurons (NeuN, red) threeweeks after stereotaxic intrahippocampal AAV-Crtc1-myc injection. Injection point is indicated in red
in the brain diagram. Insets, Magnified images of the selected regions (square) showing Crtc1-myc localization in the neuronal nucleus (left inset) or cytoplasm (right inset). Scale bar, 50m. B,
Increased Crtc1-myc and total Crtc1 mRNAs normalized to Gapdh in AAV-Crtc1-myc-injected mice. Data are the mean	 SEM (n 4–5 mice/group); *p 0.05, **p 0.001, compared with
AAV-GFP-injected control mice. C, Crtc1-myc protein levels in injected mice. Data are the mean	 SEM (n 4 mice/group); **p 0.001 compared with AAV-GFP-injected control mice. D,
Overexpression of AAV-Crtc1 rescues spatial learning (top panel) and long-termmemory (middle and bottompanels) deficits in 6-month-old APPSw,Indmice. Data indicate percentage of time in the
target quadrant or number of target platform crossings compared with the average of time or number of crossings in the three other quadrants, respectively. Data are the mean	 SEM (n 8
mice/group); *p 0.002, **p 0.0001, compared with controls or the average of other quadrants as determined by two-way ANOVA. E, Crtc1-dependent gene expression normalized to the
geometricmeanofGapdh,Hprt1, and Tbp in hippocampus of AAV-injectedmice. Data represents themean	 SEM (n 4–5mice/group); *p 0.05 comparedwithWT-GFP; #p 0.05 compared
with APP-GFP mice. Statistical analyses were determined by one- or two-way ANOVA followed by Student-Newman–Keuls post hoc test.
5784 • J. Neurosci., April 23, 2014 • 34(17):5776–5787 Parra-Damas, Valero et al. • CRTC1 Signaling in Alzheimer’s Disease
Arc mRNA expression across AD stages (F(3,64) 4.7, p 0.005)
with significant reduced levels at early (Braak I–II) and interme-
diate (Braak III–IV) pathological stages compared with controls
(one-way ANOVA, p  0.02; Fig. 5A). Similarly, Nr4a2 levels
were downregulated at Braak III–IV and V–VI stages compared
with controls (p 0.04; Fig. 5A). By contrast, Cyr61 and CRTC1
transcripts were not significantly changed during AD pathologi-
cal progression (Fig. 5A). Biochemical analysis revealed a reduc-
tion of both total and phosphorylated CRTC1 in human
hippocampus at Braak IV and V–VI pathological stages (Fig. 5B).
These results indicated dysregulation of CRTC1-dependent tran-
scription associated with decreased CRTC1 levels in human brain
at intermediate Braak III–VI pathological stages.
Discussion
Gene expression changes in the brain occur at early AD stages
(Blalock et al., 2004; Bossers et al., 2010; Twine et al., 2011), but
whether deregulation of brain transcriptome causes memory deficits
in this disease is still unclear. Genome-wide transcriptome analyses
revealed significant differences in genes related to neurotransmis-
sion, synaptic plasticity, learning/memory, and oxidative phosphor-
ylation in the hippocampus of memory trained APPSw,Ind mice,
whereas AD was the pathway with the highest number of changed
genes relative to those of the term. Specifically, a Crtc1-dependent
gene program related to synaptic function and plasticity was dereg-
ulated at early AD-related pathological and cognitive stages. Age-
dependent Crtc1 transcriptional changes occurred in brain regions
affected by amyloid pathology and essential for memory encoding
(i.e., hippocampus), a result consistent with previous reports show-
ing region-, neuropathology-, and age-dependent gene changes in
AD (Liang et al., 2010; Twine et al., 2011). Notably, synaptic genes
identified in this study, including secretogranin II, GluA1, neurofila-
ment, synaptotagmin IV, Nr4a1, and Nr4a2 were previously re-
ported to be reduced in AD brains or CSF (Wakabayashi et al., 1999;
Ginsberg et al., 2000; Marksteiner et al., 2002), whereas others, in-
cluding BDNF and chromogranin A, are altered and may be novel
biomarkers at early AD cognitive stages (Li et al., 2009; Perrin et al.,
2011). Similarly,ArcandNr4a2were significantly reduced in human
hippocampus at intermediate AD pathological stages. These changes
are consistent with a decline of neurotransmission and plasticity
genes coinciding with intraneuronal A at intermediate AD stages
(Bossers et al., 2010). Similarly, Crtc1-dependent gene changes co-
incided temporally with initial amyloid accumulation and memory
deficits in APPSw,Ind transgenic mice, suggesting a casual link be-
tween these events. These transcriptome alterations are likely caused
by age-dependent A accumulation since APP,APPs, or APP CTF
are unchanged between 2 and 12 months in APPSw,Ind transgenic
mice. Therefore, we propose that changes on Crtc1-dependent genes
related to synaptic function and plasticity are associated with early
pathological progression and memory deficits in AD.
Our results indicate that neuronal activity and spatial memory
training activate a Crtc1-dependent transcriptional program that
includes, among others, genes essential for neurotransmission
(Scg2, Syt4, Rab2a, Chga), synaptic plasticity and memory (Arc,
c-fos, Nr4a1, Nr4a2, Bdnf), and neuritogenesis (Nefl). This result
agrees with previous reports showing preferential activation of
CREB transcriptional programs by neuronal activity and mem-
ory training (Guzowski et al., 2001; Benito et al., 2011). It is
interesting that Crtc1 expression is decreased by sustained neu-
Table 3. Summary of human brain samples used in the gene expression assays
Braak stage n Sex Age PMD (h) RIN
Control 16 6F/10M 49.9	 7..8 7.1	 3.6 6.22	 1.2
I–II 22 4F/18M 69.6	 10.2 6.0	 3.6 6.26	 0.9
III–IV 14 8F/6M 78.6	 6.3 5.0	 3.9 6.49	 1.0
V–VI 16 8F/8M 79.8	 7.2 7.4	 5.0 6.27	 0.9
Data are represented as mean	 SD. F, Female; M, male; PMD, postmortem delay; h, hours; RIN, RNA integrity
number.
Figure5. CRTC1 levels and transcriptional changes in humanbrain at intermediate ADpath-
ological stages. A, Levels of Arc, NR4A2, CRTC1, and CYR61 transcripts in the human hippocam-
pus at Braak 0 (Control; n 16), I–II (n 22), III–IV (n 14), and V–VI (n 16) stages. Arc
is significantly reduced at early (I–II) and intermediate (III–IV) Braak stages compared with
controls (F(3,64) 4.7, p 0.005), whereas NR4A2 is reduced at intermediate stages. Gene
changes in log2 scale relative to controls are normalized to the geometricmean of PPIA, GAPDH,
and-actin. Values represent mean	 SEM; *p 0.05, **p 0.02, comparedwith controls.
B,Western blotting and quantification of total and phosphorylated (Ser151) CRTC1 (pCRTC1) in
human hippocampus at different AD stages. Values represent mean fold change	 SEM (n
5–12per group); *p0.05 comparedwith control as determinedbyone-wayANOVA followed
by Scheffe´’s S post hoc test.
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ronal activity suggesting that a still unknown feedback regulatory
mechanism tightly controls Crtc-dependent transcription. The
mechanism underlying Crtc1 activation involves Crtc1 dephos-
phorylation at Ser151, a motif that regulates Crtc1 nuclear trans-
location and function (Espan˜a et al., 2010b; Ch’ng et al., 2012).
Crtc1 dephosphorylation seems to regulate the induction or
maintenance rather than basal CREB-dependent gene expression
since efficient recruitment of Crtc1 to specific CREB gene pro-
moters depends on synaptic activity (Fig. 3F). In addition, Crtc1-
dependent transcription depends on the specific cellular stimulus
and system, which results for instance in modest (0.5- to 4-fold)
or high (5- to 100-fold) gene activation by spatial memory or in
vitro synaptic stimulation, respectively. Similar to the effect of
Crtc1 ShRNA,Nr4a1-2 are reduced by 30 –50% in the hippocam-
pus of Crtc1/ mice, an experimental model characterized by
emotional changes (Breuillaud et al., 2012). Whether sustained
Crtc-dependent transcription in our experimental conditions is
due to the remaining 10 –20% Crtc1 expression, the functional
redundancy of Crtc2, and/or alternative transcriptional mecha-
nisms need further investigation.
Our findings also provide strong evidence that Crtc1 dysfunction
is associated with hippocampal-dependent transcriptome and
memory impairments. First, Crtc1-mediated transcriptional
changes are evident in the hippocampus of memory trained but not
naive APPSw,Ind mice, which agrees with the genome-wide transcrip-
tome results showing major gene changes after cognitive stimula-
tion. Second, age-related CREB gene changes are specific for genes
dependent on Crtc1, whereas genes activated independently of Crtc1
(Cyr61, Egr1, or Tob1; Ravnskjaer et al., 2007; Espan˜a et al., 2010b),
are unaffected in APPSw,Ind mice. Although changes inArc, c-fos, and
Nr4a1were previously observed in APP transgenic mice (Palop et al.,
2005; Espan˜a et al., 2010b), its contribution to memory loss was
unclear. Our results showing that Crtc1 gene transfer efficiently res-
cued spatial memory impairments by enhancing the expression of
specific subset of Crtc1-dependent genes strongly indicate a role of
Crtc1 dysfunction on memory deficits at early AD-related stages.
Several mechanisms have been proposed to underlie Crtc1 dysfunc-
tion in neurons including changes on kinases or phosphatases (i.e.,
calcineurin), synapse-nuclear translocation, Crtc1 acetylation, or
CREB glycosylation (Espan˜a et al., 2010b; Jeong et al., 2012; Rexach
et al., 2012; Ch’ng et al., 2012). Our results suggest that impaired
Crtc1 dephosphorylation at Ser151 and nuclear translocation in the
CA1/CA3 hippocampus may result in Crtc1-dependent transcrip-
tional changes. However, we cannot rule out the possibility that al-
tered Crtc1 levels in advanced AD stages or disrupted activation of
CREB might also contribute to CREB transcriptional changes in AD
(Pugazhenthi et al., 2011).
Previous studies showed that pharmacological and genetic
activation of CREB signaling ameliorate synaptic and memory defi-
cits in AD transgenic mice (Vitolo et al., 2002; Gong et al., 2004;
Smith et al., 2009; Caccamo et al., 2010; Yiu et al., 2011). Similarly,
Crtc1 gene transfer reversed early A-induced Crtc1 transcriptome
changes and spatial memory deficits. Notably, enhancing expression
of a specific subset of CREB target genes was sufficient to reverse
learning and memory deficits in APP mice. By contrast, Crtc1 over-
expression in vivodid not affect c-fosor decreased CREB target genes
activated independently of Crtc1, such as Cyr61 and Chga. This dif-
ferential effect on gene transcription could be due to the preferential
binding of Crtc1/CREB to specific Crtc1 target promoters (i.e., Arc,
Nr4a1, Nr4a2…) in detrimental of Crtc1-independent CREB pro-
moters (Zhang et al., 2005), epigenetic changes caused by binding of
Crtc1 to the CBP/CREB complex (Ravnskjaer et al., 2007), and/or a
differential timing of RNA polymerase II occupancy over specific
promoters and enhancers (Saha et al., 2011). However, spatial learn-
ing and memory were similar in WT mice after Crtc1 delivery, a
result that contrasts with enhancement of contextual memory by
Crct1 overexpression (Sekeres et al., 2012). This apparent discrep-
ancy could be due to distinct neural circuits involved in these mem-
ory tasks (associative vs spatial) and different gene-delivered vectors
(Herpes simplex virus vs adeno-associated virus) targeting different
neuronal populations. Finally, synapse loss and dysfunction tightly
correlates with cognitive decline at initial AD stages (Terry et al.,
1991; Masliah et al., 2001). Because Crtc1 regulates expression of
multiple proteins involved in synaptic morphology, function, and
plasticity, our results raise the possibility that Crtc1 dysfunction un-
derlies synapse dysfunction in AD. In conclusion, targeting specifi-
cally Crtc1, instead of affecting globally CREB signaling, can
represent a novel therapeutic avenue to ameliorate transcriptome,
synaptic, and cognitive changes at early AD stages.
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